Cetera Investment Advisers Increases Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Cetera Investment Advisers grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 8.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,032 shares of the company's stock after acquiring an additional 953 shares during the period. Cetera Investment Advisers' holdings in Medpace were worth $3,997,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Invesco Ltd. boosted its stake in Medpace by 91.8% during the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after purchasing an additional 519,186 shares during the period. Proficio Capital Partners LLC boosted its position in shares of Medpace by 34,497.4% in the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after acquiring an additional 241,827 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Medpace in the fourth quarter worth $78,144,000. Norges Bank bought a new position in Medpace during the fourth quarter worth $69,859,000. Finally, GW&K Investment Management LLC raised its stake in Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after purchasing an additional 133,379 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on MEDP shares. William Blair restated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird decreased their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Finally, Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $349.30.

Medpace Stock Performance

Shares of Medpace stock traded up $0.32 on Monday, reaching $305.98. 188,958 shares of the company's stock were exchanged, compared to its average volume of 350,640. The company has a market capitalization of $8.79 billion, a P/E ratio of 24.23, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77. The firm's 50-day moving average is $304.24 and its two-hundred day moving average is $327.86.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same quarter in the prior year, the business earned $3.20 earnings per share. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now directly owns 2,998 shares of the company's stock, valued at $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.